$12.25 Million Settlement
Shoddy installation of natural gas lines at pork plant alleged
A massive natural gas explosion that ripped through a pork-processing plant in St. Joseph, Mo., killing one person and injuring 14, has led to settlements totaling $12.25 million. Read More >
Mark Hutton is featured in Wichita Magazine's March 2008 issue as one of Wichita's Top Attorneys.
The results come from a nationwide survey of attorneys conducted by Woodward/White, Inc., a trusted research firm that publishes the Best Lawyers in America. Mark Hutton was previously chosen by his professional colleagues as one of the Best Lawyers in America 2009. Mark Hutton is best known for his practice in the fields of medical malpractice, personal injury litigation, product liability litigation and mass tort litigation. Mark Hutton considers it a privilege and an honor to be voted by his peers as one of Wichita's Top Attorneys and America's Best Lawyers.
Hutton & Hutton Seek Reimbursements For Kansans From Makers Of Vytorin ®
On January 14, 2008, the pharmaceutical giants of Merck & Co. and Schering-Plough Corp., which together manufacture, market and sell Vytorin ® , finally released the results of a study regarding how well Vytorin ® works to lower total cholesterol and reduce clogged arteries. The ENHANCE study, completed in April 2006, established that the very-expensive name-brand Vytorin ® worked no better at lowering total cholesterol than high-doses of its lower-priced generic ingredient, simvastatin, and actually accelerated placque build-up in the arteries, a major risk factor for heart disease and stroke. Read More >
Hutton & Hutton Wins $982,143 Jury Verdict
A Sedgwick County jury awarded $982,143 to the family of James “Jeff” Duncan, a 38 year old Wichita man who on February 28, 2004, went to the West Wichita Family Physicians, P.A.’s minor emergency office (“WWMEO”) complaining of significant shortness of breath on exertion. No offer of settlement was ever made by the defendant physician. Read More >
Recent News Archive >
|
|
FDA recalls Hydroxycut products
The U.S. Food and Drug Administration (FDA) is warning consumers to immediately stop using Hydroxycut products, popular dietary supplements used for weight loss, energy enhancers and fat burners, because some Hydroxycut products are associated with a serious number of liver injuries. The FDA has received 23 reports of serious health problems ranging from jaundice and elevated liver enzymes to liver damage requiring liver transplant. The reports include the 2007 death of a 19-year-old man due to liver failure. Other health problems reported include seizures, cardiovascular problems and rhabdomyolysis, a type of muscle damage that can lead to other serious health problems such as kidney failure. For more information click here.
Atrazine Litigation
Hutton & Hutton has teamed up with the renowned Dallas-based law firm, Baron & Budd, P.C., to protect the rights of every Kansan to clean drinking water. Together, we seek to recover from the makers of Atrazine, a fine herbicide-of-choice, the costs for clean up and other damages that Kansas municipal water providers have suffered as a result of Atrazine pollution. We find no fault with Atrazine itself, the farmers who use it, or the merchants who sell it; just with the folks who make it. And Kansas citizens and water providers should not have to pay to clean up the mess that Atrazine's makers have made.
Our colleagues at Baron & Budd have summarized information about Atrazine itself and the litigation against its makers very well. With their permission, we have reproduced this information. Follow this link to learn more about Atrazine.
Hutton & Hutton welcome hearing from you if you would like to discuss Atrazine pollution affecting your water district. We would be glad to meet with you personally and present the facts to those who make decisions on these types of matters. Email us or call and ask for any of us: Mark, Andy, or Debs.
Raptiva -- Psoriasis Drug Withdrawn From Market
On April 8, 2009, Genentech and FDA notified healthcare professionals of the voluntary, phased withdrawal of Raptiva (efalizumab), a medication for treatment of psoriasis, from the U.S. market due to a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML), a rare brain infection. By June 8, 2009, Raptiva will no longer be available in the United States. Prescribers are being asked not to initiate Raptiva treatment for any new patients. Prescribers should immediately begin discussing with patients currently using Raptiva how to transition to alternative therapies. The FDA strongly recommends that patients work with their health care professional to transition to alternative therapies for psoriasis.
As of February 2009 there were three confirmed, and one possible report of PML in patients using Raptiva. Symptoms of PML include a new or sudden change in thinking, balance, strength, talking, walking or vision. Call your doctor right away if you have any of these symptoms or if anyone close to you notices a new or sudden change in your thinking. You should also call your doctor to discuss changing to another psoriasis medicine.
Contact Hutton & Hutton for more information.
Reglan -- Black Box Warning
After decades on the market, on February 26, 2009, the FDA ordered manufacturers of the drug Reglan and its generic equivalents, including Metoclopramide hydrochloride, to add a Black Box Warning to their drug labels about the risk of its long-term or high-dose use, and required them to warn patients directly about the potential risks of the drug, especially in light of its limited benefits. Reglan is indicated for short-term treatment of gastroesophageal reflux (GERD) and diabetic gastroparesis, which are chronic conditions. Reglan has also been prescribed for women who are pregnant and experiencing morning sickness, breastfeeding mothers, infants and children and for nausea assocated with migraines. Chronic use of Reglan and other metoclopramide-containing drugs has been linked to Tardive Dyskinesia, a potentially irreversible disorder characterized by involuntary and repetitive movements of the face, tongue and extremities.
Contact Hutton & Hutton for more information.
|
